CGEN — Compugen Ltd.

Compugen Ltd. (CGEN) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2025, Compugen reported approximately $145.6 million in cash, cash equivalents, and marketable securities, extending its cash runway into 2029.
• Revenue: Q4 2025 revenues were approximately $67.3 million, and total revenues for the year were approximately $72.8 million, significantly up from $1.5 million and $27.9 million in Q4 and full year 2024, respectively. The increase was largely driven by a $65 million upfront payment from AstraZeneca related to the monetization of future royalties.
• Expenses: R&D expenses for Q4 2025 were approximately $5.5 million, and for the year, they totaled about $22.8 million, showing a decrease from the previous year due to winding down prior trials. G&A expenses also decreased slightly.
• Net Profit: The company reported a net profit of approximately $56.8 million for Q4 2025 ($0.60 per share) and a net profit of approximately $35.3 million for the full year ($0.38 per share), contrasting with net losses in the same periods of 2024.

2. Strategic Updates and Business Highlights

• Leadership Transition: Dr. Eran Ophir became CEO in September 2025, with Anat Cohen-Dayag transitioning to Executive Chair.
• Partnership with AstraZeneca: Compugen entered a strategic transaction with AstraZeneca, monetizing a portion of future rilvegostomig royalties for $65 million upfront and an additional $25 million upon BLA acceptance. Total potential milestones from this partnership increased to $195 million.
• Clinical Development: Compugen advanced its clinical programs, including the initiation of trials for COM701 and GS-0321, and expanded its clinical footprint in the U.S., Israel, and France.
• Data Presentations: Clinical updates for COM701 and GS-0321 were presented at major conferences (ESMO and SITC).

3. Forward Guidance and Outlook

• 2026 Strategic Priorities: Compugen plans to continue executing the MAIA ovarian adaptive trial, with an interim analysis expected in Q1 2027. The company aims to explore broader clinical development plans for COM701 and to advance GS-0321.
• Pipeline Focus: The company will maintain a strong emphasis on its early-stage pipeline, leveraging its AI/machine-learning-based discovery platform.

4. Bad News, Challenges, or Points of Concern

• Timeline Adjustments: The interim analysis for the MAIA trial has been pushed to Q1 2027, attributed to slower-than-anticipated site openings and event accumulation, which may raise concerns about trial progress.
• Market Competition: The landscape for immuno-oncology therapies remains competitive, particularly in the TIGIT space, which may pose risks to the commercialization of rilvegostomig.

5. Notable Q&A Insights

• COM701 Update Expectations: The upcoming Q1 2027 update will depend on data maturation, with potential paths for registration contingent on the trial's outcomes.
• Rilvegostomig Milestones: The next milestone payment from AstraZeneca is tied to BLA acceptance, with a total of $195 million in milestones remaining.
• Gilead Collaboration: Future data presentations for GS-0321 will be aligned with Gilead, with expectations for activity and safety data to be shared at scientific conferences.
• Clinical Strategy: Compugen remains confident in the differentiation of rilvegostomig due to its unique antibody format and clinical strategy compared to competitors.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and notable insights from the Q&A session, providing a balanced view of Compugen Ltd.'s current position and future outlook.